Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study

Table 2 Clinical data of patients with lSSc, lcSSc and dcSSc^a

Subset	lSSc (n= 7)	lcSSc (n= 29)	dcSSc (n= 17)
Mean age, yr (± SD)	51 ± 16	51 ± 13	55 ± 8,0
Female/male, n	6/1	21/8	9/8
Median disease duration^b (range^c)	2 (2 to 21)	6 (0 to 35)	2 (0 to 12)
Median mRSS (range)	0 (0 to 0)	4 (0 to 14)	21 (4 to 27)
Median local skin score dorsal forearm (range)	0 (0 to 0)	0 (0 to 2)	1 (0 to 3)
ACR criteria, n	0	14	17
ANA, n
Topoisomerase I	0	5	8^c
Centromere	6	14	3^c
RNA polymerase III	0	1	3
U1-RNP	0	3	0

^aACR, American College of Rheumatology; ANA, antinuclear antibodies; dcSSc, diffuse cutaneous systemic sclerosis; lSSc, limited systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; mRSS, modified Rodnan skin score; U1RNP, U1-ribonucleic protein; ^bdisease duration from first non-Raynaud's phenomenon symptom; ^cone patient had both anticentromere and anti-topoisomerase I antibodies. ^crange denotes the full interval between the smallest and largest values

ISSN: 1478-6362